MedTrace Logo

Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL

NCT06150053 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2023-11-29

No results posted yet for this study

Summary

Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.

Conditions

  • DLBCL
  • Old Age; Debility

Sponsors & Collaborators

  • University Hospital, Saarland

    lead OTHER

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2023-01-01
Completion
2023-11-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150053 on ClinicalTrials.gov